Ibrutinib (PCI-32765) in chronic lymphocytic leukemia

Hematology/Oncology Clinics of North America

Volumn 27, Issue 4, 2013, Pages 851-860

  Jain, Nitin ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B cell receptor inhibitor; Bruton tyrosine kinase inhibitor; Chronic lymphocytic leukemia; Ibrutinib; PCI 32765

Indexed keywords

B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BRUTON TYROSINE KINASE; IBRUTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; RITUXIMAB;

ANEMIA; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FOLLICULAR LYMPHOMA; HEMORRHAGIC COLITIS; HUMAN; HYPONATREMIA; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NAUSEA; NEUTROPENIA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

B-CELL RECEPTOR INHIBITOR; BRUTON TYROSINE KINASE INHIBITOR; CHRONIC LYMPHOCYTIC LEUKEMIA; IBRUTINIB; PCI-32765;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84881267213     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.01.006     Document Type: Review

References (43)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations) 2012, National Cancer Institute, Bethesda (MD), Available at:, based on November 2011 SEER data submission, posted to the SEER web site. Accessed October 5, 2012. http://seer.cancer.gov/csr/1975_2009_pops09/.
2. Gribben J.G., O'Brien S. Update on therapy of chronic lymphocytic leukemia. JClin Oncol 2011, 29(5):544-550.
3. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112(4):975-980.
4. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. NEngl J Med 2000, 343(26):1910-1916.
5. Badoux X.C., Keating M.J., Wen S., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118(13):3489-3498.
6. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111(11):5291-5297.
7. Wierda W.G., Kipps T.J., Durig J., et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117(24):6450-6458.
8. O'Brien S.M., Kantarjian H.M., Thomas D.A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98(12):2657-2663.
9. Elter T., Gercheva-Kyuchukova L., Pylylpenko H., et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011, 12(13):1204-1213.
10. Fischer K., Cramer P., Busch R., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. JClin Oncol 2011, 29(26):3559-3566.
11. Fischer K., Cramer P., Busch R., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. JClin Oncol 2012, 30(26):3209-3216.
12. Chiorazzi N., Ferrarini M. Bcell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003, 21:841-894.
13. Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103(12):4389-4395.
14. Herishanu Y., Perez-Galan P., Liu D., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117(2):563-574.
15. Burger J.A. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011, 2011:96-103.
16. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120(6):1175-1184.
17. Wiestner A. Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120(24):4684-4691.
18. Khan W.N. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 2001, 23(2-3):147-156.
19. Satterthwaite A.B., Witte O.N. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 2000, 175:120-127.
20. Smith C.I., Baskin B., Humire-Greiff P., et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. JImmunol 1994, 152(2):557-565.
21. Genevier H.C., Hinshelwood S., Gaspar H.B., et al. Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol 1994, 24(12):3100-3105.
22. Conley M.E., Dobbs A.K., Farmer D.M., et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009, 27:199-227.
23. Chen L., Widhopf G., Huynh L., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100(13):4609-4614.
24. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. JExp Med 2001, 194(11):1639-1647.
25. Davis R.E., Ngo V.N., Lenz G., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(7277):88-92.
26. Contri A., Brunati A.M., Trentin L., et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. JClin Invest 2005, 115(2):369-378.
27. Hoellenriegel J., Coffey G.P., Sinha U., et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012, 26(7):1576-1583.
28. Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13):2578-2585.
29. Buchner M., Baer C., Prinz G., et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010, 115(22):4497-4506.
30. Herman S.E., Gordon A.L., Wagner A.J., et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116(12):2078-2088.
31. Hoellenriegel J., Meadows S.A., Sivina M., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118(13):3603-3612.
32. Lannutti B.J., Meadows S.A., Herman S.E., et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117(2):591-594.
33. Pan Z., Scheerens H., Li S.J., et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007, 2(1):58-61.
34. Honigberg L.A., Smith A.M., Sirisawad M., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010, 107(29):13075-13080.
35. Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(23):6287-6296.
36. Ponader S., Chen S.S., Buggy J.J., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing invitro and invivo. Blood 2012, 119(5):1182-1189.
37. Advani RH, Sharman JP, Smith SM, etal. The Btk Inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase I study. 11th International Conference on Malignant Lymphoma Meeting Abstract. Lugano, Switzerland. June 15, 2011. p. 153a.
38. O'Brien S, Burger JA, Blum KA, etal. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up ofa phase Ib/II study. American Society of Hematology Annual Meeting Abstracts. San Diego, USA. December 13, 2011. p. 983a.
39. O'Brien S, Furman R, Coutre S, etal. The Bruton's Tyrosine kinase inhibitor ibrutinib is highly active and tolerable in relapsed or refractory and treatment naive CLL patients, updated results of a phase IB/II study. European Hematology Meeting Annual Abstracts. Amsterdam, The Netherlands. June 16, 2012. p. 542a.
40. Jaglowski SM, Jones JA, Flynn JM, etal. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. American Society of Clinical Oncology Annual Meeting Abstracts. Chicago, USA. June 4, 2012. p. 6508a.
41. Brown J, Barrientos J, Flinn I, etal. The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase Ib/II study. European Hematology Meeting Annual Abstracts. Amsterdam, The Netherlands. June 16, 2012. p. 543a.
42. Wang L, Martin P, Blum KA, etal. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. American Society of Hematology Annual Meeting Abstracts. San Diego, USA. December 13, 2011. p. 442a.
43. Available at: Accessed August 25, 2012. http://clinicaltrials.gov/ct2/show/NCT01578707%3fterm%3dibrutinib%26rank%3d6.